medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2012, Number 2

<< Back Next >>

VacciMonitor 2012; 21 (2)

Standardization of immunoenzimatic assays (ELISA) for the quantitative determination of IgG antibodies elicited by an-outer-membrane-vesicle vaccine from Neisseria meningitidis serogroups A and W135

Mandiarote A, Gutiérrez N, Valmaseda T, Sosa R, Ontivero I, Talavera A, Álvarez M, Aranguren Y, Ochoa RF, García L

Language: Spanish
References: 19
Page: 16-23
PDF size: 328.17 Kb.


ABSTRACT

Invasive meningococcal disease constitutes a worldwide health problem. Gram negative bacteria, Neisseria meningitidis is the causal agent of this disease. Plain or conjugated polysaccharide vaccines are available against four of five serogroups responsible of more than 95% of cases in the world. Because serogroup B polysaccharide is non immunogenic, some vaccine candidates, based on outer membrane proteins have been obtained and evaluated in clinical trials. Bactericidal activity determination and ELISA IgG have been used to evaluate immune response generated by antimeningococcal vaccines. The latter has been used, as potency test, to release VAMENGOC- BC® vaccine lots, produced at Finlay Institute. As a result of the collaboration with Norwegian researchers, a vaccine candidate based on outer membrane proteins against serogroups A and W135, has been obtained and evaluated in animal models. The current work describes the standardization of an ELISA method to be used in the immune response evaluation of the bivalent vaccinal candidate.


REFERENCES

  1. Harrison LH, Trotter CL, Ramsay L. Global epidemiology of meningococcal disease. Vaccine 2009;27S:B51-B63.

  2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia and Neisseria meningitidis. Lancet 2007;369:2196-210.

  3. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-63.

  4. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54:1–21.

  5. Reisinger KS, Baxter S, Block S, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: Phase III comparison of an investigational conjugate vaccine men ACWY-CRM, with the licensed vaccine Menactra. Clin Vac Immunol 2009;16:1810-5.

  6. Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734–7.

  7. Sierra GV, Campa HC, Varcacel NM, García IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseriameningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195–207.

  8. Jackson C, Lennon D, Wong S, Yan J, Stewart J, Ester P, et al. Antibody persistence following Men NZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Chile 2011;96:744-51.

  9. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. PNAS 2006;103:10834-9.

  10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. A protein measurement with the folin-phenol reagent. Biol Chem 1951;193:265-75.

  11. Borrow R, Balmer P, Millar E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005;23:2222-7.

  12. Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J, Klem A, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642–52.

  13. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Høiby EA, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis1998;177:683–91.

  14. Norheim G, Aase A, Caugant D, Høiby A, Fritzsønn E, Tangen T, et al. Development and characterisation of outer membranevesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005;23:3762-74.

  15. García L, Mandiarote A, Norheim G, González D, Reyes G, Tunheim G et al. Scale-up of process for GMP production of a serogroup A and W135 meningococcal outer membrana vesicle for Africa. In:17th International Pathogenic Neisseria Conference; 2010, Sept 11-16; Banff, Alberta, Canadá 2010. p. 227.

  16. Norheim G, Høiby A, Caugant D, Namork E, Tangen T, Fritzsønn E, Rosenqvist E. Immunogenicity and bactericidal activity inmice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease. Vaccine 2004;22:2171-80.

  17. Andersen J, Berthelsen L, Lind I. Measurement of antibodies against meningococcal capsular polysaccharide B and C in Enzyme-linked Immunosorbent Assay towards an Improved Surveillance of Meningococcal Disease. Clin Diag Lab Immunol 1997;4:345-51.

  18. Morley S, Cole M, Ison C, Camaraza MA, Sotolongo F, Anwar N, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J. 2001;20:1054-61.

  19. Plikaytis BD, Turner SH, L Gheesling L and Carlone GM. Comparisons of standard curve-fitting methods to quantitateNeisseria meningitidis group A polysaccharide antibody levelsby enzyme-linked immunosorbent assay. J Clin Microbiol 1991;29:1439-46.




2020     |     www.medigraphic.com